Spinal Muscular Atrophy Market: Navigating Therapeutic Advances towards USD 5.6 Billion by 2034, with a CAGR of 14.80% - By PMI
February 15, 2024 17:02 ET
|
PMI
Covina, Feb. 15, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Spinal Muscular Atrophy Market size was valued at about USD 1.4 Billion in 2024 and expected to grow at CAGR of...
Spinal Muscular Atrophy Market to Grow Rapidly During the Forecast Period (2019–2032), Assesses DelveInsight | Key Players - Biogen, NMD Pharma, Novartis, Roche, Biohaven Pharmaceuticals, Scholar Rock, AnnJi Pharmaceutical
October 31, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Spinal Muscular Atrophy Market to Grow Rapidly During the Forecast Period (2019–2032), Assesses DelveInsight | Key Players - Biogen, NMD Pharma,...
Spinal Muscular Atrophy Treatment Market to Reach $8.4Billion, Globally, by 2032 at 6.8% CAGR: Allied Market Research
July 18, 2023 10:00 ET
|
Allied Market Research
Portland, OR, July 18, 2023 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, “Spinal Muscular Atrophy Treatment Market By Type (Type 1, Type 2, and Others), By Route of...
Muscular Dystrophy Association Announces 2023 National Ambassador Leah Zelaya from New York
January 23, 2023 10:00 ET
|
Muscular Dystrophy Association
New York, NY, Jan. 23, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) has selected 15-year-old Leah Zelaya from Brooklyn, New York, as its 2023 MDA National Ambassador. ...
NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3
December 14, 2022 07:00 ET
|
NMD Pharma
NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3 Aarhus, Denmark, 14 December 2022 – NMD Pharma A/S, a...
NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3
December 14, 2022 01:00 ET
|
NMD Pharma
NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3 Aarhus, Denmark, 14 December 2022 – NMD Pharma A/S, a...
Biogen To Present Data At AAN Highlighting Its Innovative Marketed Treatments And Investigational Pipeline Programs For Complex Neurodegenerative Diseases
May 01, 2019 07:30 ET
|
Biogen Inc.
Data demonstrate that pre-symptomatic infants with SMA treated with SPINRAZA® (nusinersen) over three years achieved motor milestones that are more consistent with normal childhood...
La réaction de Biogen aux recommandations mises à jour de l’ACMTS concernant l’accès à SPINRAZA
March 01, 2019 20:18 ET
|
Biogen Canada
·L’Agence canadienne des médicaments et des technologies de la santé (ACMTS) a élargi ses recommandations concernant le financement par les fonds publics du traitement des patients atteints...
Biogen Responds to CADTH’s updated recommendation regarding coverage for SPINRAZA
March 01, 2019 20:18 ET
|
Biogen Canada
·Canadian Association of Drugs and Technologies in Health (CADTH) has expanded their recommendations for public reimbursement for SMA patients ·The recommendation, however, continues to limit access...
Global CNS Specific Antisense Oligonucleotide Market to Surpass US$ 6.8 Billion by 2026 – Coherent Market Insights
February 08, 2019 08:30 ET
|
CMI
SEATTLE, Feb. 08, 2019 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global CNS specific antisense oligonucleotide market is valued at US$ 883.7 million in 2017, and is projected to...